Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Mar 29, 2024

SELL
$1.06 - $2.16 $38,584 - $78,624
-36,400 Closed
0 $0
Q4 2022

Mar 29, 2024

BUY
$1.05 - $2.53 $38,220 - $92,092
36,400 New
36,400 $53.1 Million

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $121M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Kapitalo Investimentos Ltda Portfolio

Follow Kapitalo Investimentos Ltda and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kapitalo Investimentos Ltda, based on Form 13F filings with the SEC.

News

Stay updated on Kapitalo Investimentos Ltda with notifications on news.